Arcus (RCUS) CAO Alexander Azoy Exercises Options, Sells Shares

What Happened
Alexander Azoy, Chief Accounting Officer of Arcus Biosciences (RCUS), exercised 2,827 stock options on August 21, 2026 (cost $15.44 per share; total exercise cost $43,649) and sold the same 2,827 shares in an open-market transaction that day at $30.00 per share for gross proceeds of $84,810. The filing also reports the related derivative conversion (exercise) entry. The transactions were effected pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: August 21, 2026. Form 4 filed August 24, 2026 (appears timely).
• Exercise: 2,827 shares @ $15.44 = $43,649 (code M).
• Sale: 2,827 shares @ $30.00 = $84,810 (code S).
• Derivative disposition: 2,827 @ $0 reported (reflects the option conversion).
• Net immediate effect: no net change in outstanding shares held from these trades (exercise then immediate sale).
• Footnotes: F1 = trades done under a Rule 10b5-1 plan; F2 = reported ownership counts include unvested RSUs; F3 = the option vests in 48 equal monthly installments beginning after Jan 1, 2024.

Context
This was an exercise followed by an immediate open-market sale (a common cashless-style transaction) rather than a standalone buy. Sales do not necessarily indicate a change in the insider’s view of the company—these were executed under a predetermined 10b5-1 plan. The filing shows the gross proceeds and exercise cost; after taxes/withholdings the net cash retained will be lower.